GI Markets Study: IBD, Crohn's Sectors to Grow, GERD to Shrink

However, the market for gastrointestinal disorder therapeutics will decline in that period, due to negative growth of the gastroesophageal reflux disease therapeutics as patents lapse and more drugs become generic.

Patent expirations of major drugs have increased competition, driving further consolidation and more use of licensing agreements.

Independent GI practices shrinks as reimbursements fall 38% over a decade

Between 2012 and 2020, the number of GI practices decreased by more than 650, 14%, even as the total number…

Endoscopy at scale: The reprocessing best practices separating high-performing teams

Endoscopies are among the most common procedures in the U.S. with millions performed each year. For providers to safely and…

Missouri hospital adds noninvasive liver tumor treatment

Mercy Hospital St. Louis will begin treating liver tumors with the Edison histotripsy system, a noninvasive technology that uses sound…

GI Markets Study: IBD, Crohn’s Sectors to Grow, GERD to Shrink

Related Articles on Gastrointestinal Drugs:

Next Up in GI & Endoscopy

Independent GI practices shrinks as reimbursements fall 38% over a decade

Endoscopy at scale: The reprocessing best practices separating high-performing teams

Missouri hospital adds noninvasive liver tumor treatment

Related Articles on Gastrointestinal Drugs:

Getting Documentation Right the First Time

Next Up in GI & Endoscopy

Independent GI practices shrinks as reimbursements fall 38% over a decade

Endoscopy at scale: The reprocessing best practices separating high-performing teams

Missouri hospital adds noninvasive liver tumor treatment

Join the 40,000+ ASC leaders who start their day with Becker's